Academic Journal
Q1CA: A Cancer Journal for Clinicians
About CA: A Cancer Journal for Clinicians
About Ca-A Cancer Journal for Clinicians
Ca-A Cancer Journal for Clinicians is a peer-reviewed scholarly journal published by John Wiley and Sons Inc (United States). It focuses on Medicine Hematology Oncology. Publication coverage spans 1950-2026.
Key indicators: ISSN 00079235, 15424863; H-index 236; Impact Factor 685.2; 154 quartile.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (236): Exceptionally high — 236 articles have each been cited at least 236 times. This indicates deep, sustained influence in the field.
- Quartile (154): Ranked 154 among journals in its subject category — position relative to category peers.
- Impact Factor (685.2): Average citations per recent article. Above 10 places it among the most-cited journals in its field.
Publishing in Ca-A Cancer Journal for Clinicians
As a top-tier journal, this venue is highly selective. Expect rigorous peer review, low acceptance rates, and intense competition. Submit only your strongest, most significant work.
- Scope fit: Confirm your research aligns with Medicine Hematology Oncology. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
- Submission: Submit via the official journal website.
- Charges: Listed APC: No charge under CC BY-NC-ND; other licences may incur an APC. See author guidelines.. Verify current fees with the publisher.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Ca-A Cancer Journal for Clinicians?
00079235, 15424863.
Who publishes Ca-A Cancer Journal for Clinicians?
John Wiley and Sons Inc.
What are Ca-A Cancer Journal for Clinicians's metrics?
Impact Factor 685.2; H-index 236.
Where do I submit to Ca-A Cancer Journal for Clinicians?
Via the official website.
Is Ca-A Cancer Journal for Clinicians peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Publisher information for authors
Author requirements
Send a proposed outline and abstract, author information and manuscript length for approval before submitting an unsolicited paper. Approved manuscripts use ScholarOne. Unsolicited case reports and letters are not considered.
Peer review
Editors select external reviewers and decide whether to accept a manuscript.
Fees and licence
The author guidelines state that CC BY-NC-ND publication is free; other required licences can incur an APC. There are no submission, page or colour charges.
2025 publisher-reported metrics
Journal Impact Factor 685.2; CiteScore 649.8; acceptance rate 31%. Median submission-to-first-decision: 2 days; submission-to-acceptance: 28 days; acceptance-to-publication: 39 days. These statistics do not predict an individual manuscript’s outcome.
Publisher sources checked 2026-10-03. Policies can change; follow the linked instructions when preparing a submission.
Source-backed journal facts
Topics in published research
Advances in Oncology and Radiotherapy; Global Cancer Incidence and Screening; Cancer Treatment and Pharmacology; BRCA gene mutations in cancer; Economic and Financial Impacts of Cancer; Cancer survivorship and care.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The journal covers cancer prevention, screening, treatment, supportive care and survivorship. Most articles are commissioned reviews. Unsolicited proposals and high-impact clinical trials require editorial approval before manuscript submission.
Recent Research Articles
Latest publications matched automatically by ISSN.
Recurrent prostate adenocarcinoma after radical prostatectomy: Principles of multidisciplinary management across a spectrum of disease
Amar U. Kishan, Yulia Zekster, Adam E. Singer, Kekoa Taparra et al.
2026-09 · DOI: 10.3322/caac.70111Advances in therapeutic approaches to gastric cancer
Feng Wang, Zi‐Xian Wang, Yu‐Jing Zhang, Ye He et al.
2026-09 · DOI: 10.3322/caac.70103Early stage non–small cell lung cancer: Toward a risk‐adaptive paradigm in the era of biologic precision
Chaoqi Zhang, Xuanyu Gu, Pan Wang, Dongyu Li et al.
2026-09 · DOI: 10.3322/caac.70100Cancer statistics for Hispanic/Latino people, 2026
Anatu H. Saka, Tyler B. Kratzer, Angela N. Giaquinto, Natalia Mazzitelli et al.
2026-09 · DOI: 10.3322/caac.70107A changing landscape in gastric cancer
Lindsay M. Hannan, Vaia Florou
2026-09 · DOI: 10.3322/caac.70113Redefining early stage non–small cell lung cancer: The dawn of the risk‐adaptive and biologically precise era
Clarissa Mathias, Fabio Ynoe Moraes
2026-09 · DOI: 10.3322/caac.70102Thank You to Reviewers 2026
2026-09 · DOI: 10.3322/caac.70108The new (version 9) American Joint Committee on Cancer (AJCC) tumor‐node‐metastasis (TNM) staging protocol for carcinoma of the vulva
Alexander B. Olawaiye, Elliot A. Asare, Ian S. Hagemann, Priya R. Bhosale et al.
2026-09 · DOI: 10.3322/caac.70104Issue Information
2026-09 · DOI: 10.3322/caac.70099Correction to “Serious mental illness and cancer: A call to action for equitable care”
2026-07 · DOI: 10.3322/caac.70101Serious mental illness and cancer: A call to action for equitable care
Daniel McFarland, Cristiane Bergerot, Pernille Bidstrup, Miri Cohen et al.
2026-07 · DOI: 10.3322/caac.70095Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries
Hyuna Sung, Adalberto M. Filho, Mathieu Laversanne, Jacques Ferlay et al.
2026-07 · DOI: 10.3322/caac.70090Discordant molecular biomarkers in unfavorable intermediate‐risk localized prostate cancer
Michael Rooney, Krishnan R. Patel, Shalin Shah, Justin R. Gregg et al.
2026-07 · DOI: 10.3322/caac.70105Metastasis‐directed radiation therapy may improve progression‐free survival in patients with oligometastatic solid tumors
Carrie Printz
2026-07 · DOI: 10.3322/caac.70098Daraxonrasib significantly improves overall and progression‐free survival in patients with previously treated metastatic pancreatic cancer
Carrie Printz
2026-07 · DOI: 10.3322/caac.70097Accurate data as the foundation of equitable cancer control: Lessons from global cancer statistics 2024 and the complexity of ovarian cancer
Christina R. Washington, Kathleen N. Moore, Isabelle L. Ray‐Coquard
2026-07 · DOI: 10.3322/caac.70096Extranodal natural killer/T‐cell lymphoma: From fatal to curable
Jie Xiong, Yok‐Lam Kwong, Laurence de Leval, Shu‐Nan Qi et al.
2026-07 · DOI: 10.3322/caac.70094Issue Information
2026-07 · DOI: 10.3322/caac.70081Reviews
Community Reviews
Version History
October 9, 2026 at 9:16 am
January 12, 2025